Promise of autologous CD34+ stem/progenitor cell therapy for treatment of cardiovascular disease

Megha Prasad, Michel T. Corban, Timothy D. Henry, Allan B. DIetz, Lilach O. Lerman, Amir Lerman

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


CD34+ cells are haematopoietic stem cells used therapeutically in patients undergoing radiation or chemotherapy due to their regenerative potential and ability to restore the haematopoietic system. In animal models, CD34+ cells have been associated with therapeutic angiogenesis in response to ischaemia. Several trials have shown the potential safety and efficacy of CD34+ cell delivery in various cardiovascular diseases. Moreover, Phase III trials have now begun to explore the potential role of CD34+ cells in treatment of both myocardial and peripheral ischaemia. CD34+ cells have been shown to be safe and well-tolerated in the acute myocardial infarction (AMI), heart failure, and angina models. Several studies have suggested potential benefit of CD34+ cell therapy in patients with coronary microvascular disease as well. In this review, we will discuss the therapeutic potential of CD34+ cells, and describe the pertinent trials that have used autologous CD34+ cells in no-options refractory angina, AMI, and heart failure. Lastly, we will review the potential utility of autologous CD34+ cells in coronary endothelial and microvascular dysfunction.

Original languageEnglish (US)
Pages (from-to)1424-1433
Number of pages10
JournalCardiovascular research
Issue number8
StatePublished - Jul 1 2020


  • Acute coronary syndromes
  • CD34
  • Cardiovascular diseases
  • Coronary endothelial dysfunction
  • Coronary microvascular dysfunction
  • Endothelial progenitor cells
  • Heart failure
  • Refractory angina

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Promise of autologous CD34+ stem/progenitor cell therapy for treatment of cardiovascular disease'. Together they form a unique fingerprint.

Cite this